News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
596,119 Results
Type
Article (42860)
Company Profile (317)
Press Release (552942)
Section
Business (167493)
Career Advice (2446)
Deals (30299)
Drug Delivery (107)
Drug Development (78700)
Employer Resources (149)
FDA (14401)
Job Trends (12995)
News (295789)
Policy (28507)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (14)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (7)
2024 Genetown Standard (8)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (6)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Pharm Country Elite (1)
Academia (2670)
Academic (1)
Accelerated approval (5)
Adcomms (26)
Allergies (79)
Alliances (42881)
ALS (91)
Alzheimer's disease (1425)
Antibody-drug conjugate (ADC) (127)
Approvals (14390)
Artificial intelligence (239)
Autoimmune disease (20)
Automation (14)
Bankruptcy (325)
Best Places to Work (10700)
BIOSECURE Act (15)
Biosimilars (92)
Biotechnology (257)
Bladder cancer (65)
Brain cancer (28)
Breast cancer (255)
Cancer (2039)
Cardiovascular disease (178)
Career advice (2053)
Career pathing (31)
CAR-T (147)
Cell therapy (414)
Cervical cancer (18)
Clinical research (63612)
Collaboration (767)
Compensation (340)
Complete response letters (25)
COVID-19 (2562)
CRISPR (42)
C-suite (227)
Cystic fibrosis (101)
Data (1982)
Decentralized trials (2)
Denatured (15)
Depression (48)
Diabetes (245)
Diagnostics (5802)
Digital health (14)
Diversity (4)
Diversity, equity & inclusion (40)
Drug discovery (115)
Drug pricing (101)
Drug shortages (22)
Duchenne muscular dystrophy (91)
Earnings (61437)
Editorial (35)
Employer branding (21)
Employer resources (136)
Events (89263)
Executive appointments (664)
FDA (15488)
Featured Employer (43)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (687)
Gene editing (105)
Generative AI (20)
Gene therapy (307)
GLP-1 (720)
Government (4230)
Grass and pollen (4)
Guidances (46)
Healthcare (17261)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (119)
Indications (27)
Infectious disease (2697)
Inflammatory bowel disease (143)
Inflation Reduction Act (11)
Influenza (49)
Intellectual property (88)
Interviews (524)
IPO (14232)
IRA (45)
Job creations (2738)
Job search strategy (1684)
Kidney cancer (10)
Labor market (18)
Layoffs (444)
Leadership (19)
Legal (6048)
Liver cancer (71)
Lung cancer (303)
Lymphoma (128)
Machine learning (4)
Management (52)
Manufacturing (249)
MASH (68)
Medical device (11093)
Medtech (11097)
Mergers & acquisitions (16523)
Metabolic disorders (654)
Multiple sclerosis (73)
NASH (23)
Neurodegenerative disease (96)
Neuropsychiatric disorders (31)
Neuroscience (1949)
NextGen: Class of 2025 (5975)
Non-profit (4115)
Northern California (2257)
Now hiring (34)
Obesity (349)
Opinion (231)
Ovarian cancer (73)
Pain (82)
Pancreatic cancer (76)
Parkinson's disease (145)
Partnered (19)
Patents (203)
Patient recruitment (96)
Peanut (47)
People (53854)
Pharmaceutical (56)
Pharmacy benefit managers (13)
Phase I (19968)
Phase II (28100)
Phase III (20936)
Pipeline (1068)
Podcasts (68)
Policy (117)
Postmarket research (2390)
Preclinical (8416)
Press Release (60)
Prostate cancer (94)
Psychedelics (37)
Radiopharmaceuticals (255)
Rare diseases (385)
Real estate (4479)
Recruiting (60)
Regulatory (20202)
Reports (25)
Research institute (2274)
Resumes & cover letters (360)
Rett syndrome (4)
RNA editing (4)
RSV (37)
Schizophrenia (72)
Series A (120)
Series B (80)
Service/supplier (3)
Sickle cell disease (54)
Southern California (2029)
Special edition (13)
Spinal muscular atrophy (153)
Sponsored (27)
Startups (3165)
State (2)
Stomach cancer (14)
Supply chain (54)
Tariffs (10)
The Weekly (52)
United States (19740)
Vaccines (637)
Venture capitalists (36)
Webinars (11)
Weight loss (242)
Women's health (26)
Worklife (16)
Date
Today (117)
Last 7 days (660)
Last 30 days (2600)
Last 365 days (32037)
2025 (7908)
2024 (33526)
2023 (37471)
2022 (48408)
2021 (52018)
2020 (49977)
2019 (42539)
2018 (32084)
2017 (29605)
2016 (28150)
2015 (32900)
2014 (25341)
2013 (20525)
2012 (21738)
2011 (22667)
2010 (20372)
Location
Africa (742)
Alabama (50)
Alaska (4)
Arizona (165)
Arkansas (13)
Asia (36240)
Australia (7207)
California (5220)
Canada (1797)
China (456)
Colorado (231)
Connecticut (223)
Delaware (128)
Europe (81253)
Florida (767)
Georgia (175)
Idaho (55)
Illinois (455)
India (22)
Indiana (259)
Iowa (6)
Japan (141)
Kansas (92)
Kentucky (21)
Louisiana (8)
Maine (51)
Maryland (798)
Massachusetts (3878)
Michigan (194)
Minnesota (327)
Mississippi (2)
Missouri (74)
Montana (24)
Nebraska (22)
Nevada (50)
New Hampshire (65)
New Jersey (1506)
New Mexico (25)
New York (1500)
North Carolina (880)
North Dakota (5)
Northern California (2257)
Ohio (168)
Oklahoma (11)
Oregon (32)
Pennsylvania (1127)
Puerto Rico (9)
Rhode Island (24)
South America (1016)
South Carolina (16)
South Dakota (1)
Southern California (2029)
Tennessee (84)
Texas (761)
Utah (157)
Virginia (121)
Washington D.C. (52)
Washington State (484)
West Virginia (3)
Wisconsin (43)
596,119 Results for "tarveda therapeutics fomerly known as blend therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
January 27, 2025
·
3 min read
Press Releases
Celltrion’s Remdantry™, previously known as Inflectra®, will be available in Canada as of April 1, 2025
March 27, 2025
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Accent Therapeutics to Present Data on Lead Programs ATX-559 and ATX-295 at the 2025 American Association for Cancer Research Annual Meeting
March 25, 2025
·
5 min read
Layoffs
Repare Therapeutics to Cut Staff Again, This Time by 75%
The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 employees as it works to advance two Phase I clinical programs.
February 25, 2025
·
2 min read
·
Angela Gabriel
Press Releases
Starton Therapeutics to Present Poster at the American Association for Cancer Research (AACR) Annual Meeting 2025
March 27, 2025
·
2 min read
Press Releases
PANTHERx® Rare Selected by Soleno Therapeutics for the Distribution of VYKAT™ XR
March 31, 2025
·
2 min read
Press Releases
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
March 25, 2025
·
5 min read
Press Releases
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
April 1, 2025
·
9 min read
Immunology and inflammation
Gilead Continues Diversification Drive With Potential $1.7B Inflammation Pact With LEO
Gilead’s investment will let it assess the therapeutic potential of targeting STAT6, a transcription factor involved in IL-4 and IL-13 signaling, which in turn are known inflammatory targets.
January 13, 2025
·
2 min read
·
Tristan Manalac
1 of 59,612
Next
